DNA-based therapeutics and DNA delivery systems: A comprehensive review

AAPS Journal

Volumn 7, Issue 1, 2005, Pages

  Patil, Siddhesh D ^a   Rhodes, David G ^a   Burgess, Diane J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

DNA delivery systems; Gene therapy; Liposomes; Nonviral vectors; Nucleic acid therapeutics; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ADVEXIN; ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; APTAMER; CARBOPLATIN; CGP 69846A; CHITOSAN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DENDRIMER; DEXAMETHASONE; DNA; DNA VACCINE; FLUCYTOSINE; FLUDARABINE; FLUOROURACIL; FOMIVIRSEN; GENDICINE; ISIS 3521; LIPOSOME; OBLIMERSEN; PACLITAXEL; PEGAPTANIB; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; RIBOZYME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CROHN DISEASE; DISEASE CONTROL; DISEASE COURSE; DNA SEQUENCE; DNA STRUCTURE; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG UPTAKE; GENE DELIVERY SYSTEM; GENE INDUCTION; GENE TARGETING; HEAD AND NECK CARCINOMA; HUMAN; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PREDICTION; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS; REVIEW; SUICIDE GENE THERAPY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANTISENSE ELEMENTS (GENETICS); APTAMERS, NUCLEOTIDE; BIOLOGICAL TRANSPORT; DNA; DNA, CATALYTIC; DNA, RECOMBINANT; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; LIPOSOMES; PLASMIDS; RNA, CATALYTIC; RNA, SMALL INTERFERING; TRANSGENES;

EID: 19444375104     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070109     Document Type: Review

References (159)

1. Crooke ST. An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev. 1998;8:115-122.
2. Stull RA, Szoka FC Jr. Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharm Res. 1995;12:465-483.
3. Patil SD, Burgess DJ. DNA-based Biopharmaceuticals: therapeutics for the 21st Century. AAPS Newsmagazine. 2003;6 (12):27.
4. Baker BF. The role of antisense oligonucleotides in the wave of genomic information. Nucleosides Nucleotides Nucleic Acids. 2001;20(4-7):397-399.
5. Van Ommen GJB, Bakker E, Den Dunnen JT. The human genome project and the future of diagnostics, treatment, and prevention. Lancet. 1999;354(suppl 1):5-10.
6. Uherek C, Wels W. DNA-carrier proteins for targeted gene delivery. Adv Drug Deliv Rev. 2000;44(2-3):153-166.
7. Johnston SA, Talaat AM, McGuire MJ. Genetic Immunization What's in a Name? Arch Med Res. 2002;33:325-329.
8. Denny WA. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol. 2003;1:48-70.
9. Denny WA, Wilson WR. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. J Pharm Pharmacol. 1998;50:387-394.
10. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 1995;2:702-709.
11. Bentires-Alj M, Hellin A-C, Lechanteur C, et al. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther. 2000;7:20-26.
12. Anderson WF. Prospects for human gene therapy. Science. 1984;226:401-409.
13. Fitzsimons HL, Bland RJ, During MJ. Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods. 2002;28(2):227-236.
14. Walther W, Stein U. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. Journal of Molecular Medicine (Berlin). 1996;74:379-392.
15. Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther. 1997;8:2019-2029.
16. Paillard F. Promoter attenuation in gene therapy: causes and remedies. Hum Gene Ther. 1997;8:2009-2010.
17. Weeratna RD, Wu T, Efler SM, Zhang L, Davis HL. Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters. Gene Ther. 2001;8:1872-1878.
18. Greco O, Marples B, Dachs GU, Williams KJ, Patterson AV, Scott SD. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther. 2002;9:1403-1411.
19. Anderson WF. Human gene therapy. Nature (London). 1998;392(suppl 6679)25-30.
20. Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist. 2002;7:46-59.
21. Otsu M, Candotti F. Gene therapy in infants with severe combined immunodeficiency. BioDrugs. 2002;16:229-239.
22. China OKs Gene Therapy Drug. Genetic Engineering News. 2003:6.
23. Galanis E, Russell S. Cancer gene therapy clinical trials: lessons for the future. Br J Cancer. 2001;85:1432-1436.
24. Mulherkar R. Gene therapy for cancer. Curr Sci. 2001;81:555-560.
25. Baekelandt V, De Strooper B, Nuttin B, Debyser Z. Gene therapeutic strategies for neurodegenerative diseases. Curr Opin Mol Ther. 2000;2:540-554.
26. Bunnell BA, Morgan RA. Gene therapy for HIV infection. Drugs Today. 1996;32:209-224.
27. Horner AA, Van Uden JH, Zubeldia JM, Broide D, Raz E. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol Rev. 2001;179:102-118.
28. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta. 1999;1489:31-43.
29. Crooke ST. Molecular mechanisms of antisense drugs: human RNase H. Antisense Nucleic Acid Drug Dev. 1999;9:377-379.
30. Engels JW, Uhlmann E. Chemistry of Oligonucleotides. In: Malvy C, ed. Pharmaceutical Aspects of Oligonucleotides. London, UK: Taylor & Francis Ltd; 2000:35-78.
31. Khatsenko O, Morgan R, Truong L. et al. Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length. Antisense Nucleic Acid Drug Dev. 2000;10:35-44.
32. Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1988;16:3209-3221.
33. Matteucci M. Structural modifications toward improved antisense oligonucleotides. Perspectives in Drug Discovery and Design. 1996;4(Antisense Therapeutics):1-16.
34. Shoji Y, Akhtar S, Periasamy A, Herman B, Juliano RL. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res. 1991;19:5543-5550.
35. Akhtar S. Antisense technology: selection and delivery of optimally acting antisense oligonucleotides. J Drug Target. 1998;5:225-234.
36. Smith L, Andersen KB, Hovgaard L, Jaroszewski JW. Rational selection of antisense oligonucleotide sequences. Eur J Pharm Sci. 2000;11:191-198.
37. Patil SD, Rhodes DG. Influence of divalent cations on the conformation of phosphorothioate oligodeoxynucleotides: a circular dichroism study. Nucleic Acids Res. 2000;28:2439-2445.
38. Agrawal S, Tan W, Cai Q, Xie X, Zhang R. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev. 1997;7:245-249.
39. Akhtar S, Hughes MD, Khan A, et al. The delivery of antisense therapeutics. Adv Drug Deliv Rev. 2000;44:3-21.
40. Crooke ST. Vitravene another piece in the mosaic. Antisense Nucleic Acid Drug Dev. 1998.8:vii-v3.
41. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev. 2002;54:715-758.
42. Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, Czubayko F. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumor cell proliferation. Oncogene. 2001;20:2101-2111.
43. Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res. 2002;62:5463-5469.
44. Javasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem. 1999;45(9):1628-1650.
45. de Soultrait VR, Lozach P-Y, Altmeyer R, Tarrago-Litvak L, Litvak S. Andreola ML. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J. Mol. Biol. 2002;324:195-203.
46. Chaloin L, Lehmann MJ, Sczakiel G, Restle T. Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res. 2002;30:4001-4008.
47. Bertrand J-R, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun. 2002;296:1000-1004.
48. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet. 2002;3:737-747.
49. Scherr M, Morgan MA, Eder M. Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem. 2003;10:245-256.
50. Kurreck J. Antisense technologies: improvement through novel chemical modifications. Eur J Biochem. 2003;270:1628-1644.
51. Martinez MA, Gutierrez A, Armand-Ugon M, et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS. 2002;16(18):2385-2390.
52. Zamore PD, Aronin N. siRNAs knock down hepatitis. Nat Med. 2003;9(3):266-267.
53. Ge Q, McManus MT, Nguyen T, et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA. 2003;100:2718-2723.
54. Wong IHN. Methylation profiling of human cancers in blood: molecular monitoring and prognostication (review). Int J Oncol. 2001;19:1319-1324.
55. Bennett RM. As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells. Antisense Res Dev. 1993;3:235-241.
56. Le Doan T. Cell binding and internalisation of oligonucleotides. S.T.P. Pharma Sciences. 2001;11:75-82.
57. Crooke ST. Delivery of oligonucleotides and polynucleotides. J Drug Target. 1995;3:185-190.
58. Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today. 2001;6:303-315.
59. Liu F, Huang L. Development of non-viral vectors, for systemic gene delivery. J Control Release. 2002;78(1-3):259-266.
60. Akhtar S, Juliano RL. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 1992;2:139-144.
61. Wu-Pong S. Alternative interpretations of the oligonucleotide transport literature: insights from nature. Adv Drug Deliv Rev. 2000;44:59-70.
62. Holmes AR, Dohrman AF, Ellison AR, Goncz KK, Gruenert DC. Intracellular compartmentalization of DNA fragments in cultured airway epithelial cells mediated by cationic lipids. Pharm Res. 1999;16:1020-1025.
63. Kamiya H, Tsuchiya H, Yamazaki J, Harashima H. Intracellular trafficking and transgene expression of viral and non-viral gene vectors. Adv Drug Deliv Rev. 2001;52:153-164.
64. Tachibana R, Harashima H, Shinohara Y, Kiwada H. Quantitative studies on the nuclear transport of plasmid DNA and gene expression employing nonviral vectors. Adv Drug Deliv Rev. 2001;52:219-226.
65. Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int J Pharm. 2001;229(1-2):1-21.
66. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol. 2000;18:33-37.
67. Agrawal S, Zhang R. Pharmacokinetics of oligonucleotides. Ciba Foundation Symposium. 1997:209(Oligonucleotides as Therapeutic Agents):60-78.
68. Yu RZ, Geary RS, Leeds JM, et al. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of ha-ras encapsulated in stealth liposomes. Pharm Rev. 1999;16:1309-1315.
69. Tam P, Monck M, Lee D, et al. Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther. 2000;7:1867-1874.
70. Kunisawa J, Nakagawa S, Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv Drug Deliv Rev. 2001;52:177-186.
71. Hope MJ, Mui B, Ansell S, Ahkong QF. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs. Mol Membr Biol. 1998;15:1-14.
72. Jaaskelainen I, Moenkkoenen J, Urtti A. Oligonucleotide-cationic liposome interactions. A physicochemical study. Biochim Biophys Acta. 1994;1195:115-123.
73. Jaaskelainen I, Sternberg B, Monkkonen J, Urtti A. Physicochemical and morphological properties of complexes made of cationic liposomes and oligonucleotides. Int J Pharm. 1998;167(1-2):191-203.
74. Monnard P-A, Oberholzer T, Luisi P. Entrapment of nucleic acids in liposomes. Biochim Biophys Acta. 1997;1329:39-50.
75. McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles for gene and drug delivery. Annu Rev Biomed Eng. 2000;2:289-313.
76. Regnier V, Tahiri A, Andre N, Lemaitre M, Le Doan T, Preat V. Electroporation-mediated delivery of 3′-protected phosphodiester oligodeoxynucleotides to the skin. J Control Release. 2000;67(2-3):337-346.
77. Huang L, Viroonchatapan E. Introduction. In: Huang L, Hung M-C, Wagner E, ed. Nonviral Vectors for Gene Therapy. San Diego, CA: Academic Press; 1999:3-22.
78. Mah C, Byrne BJ, Flotte TR. Virus-based gene delivery systems. Clin Pharmacokinet. 2002;41:901-911.
79. Lotze MT, Kost TA. Viruses as gene delivery vectors: application to gene function, target validation, and assay development. Cancer Gene Ther. 2002;9:692-699.
80. McTaggart S, Al-Rubeai M. Retroviral vectors for human gene delivery. Biotechnol Adv. 2002;20:1-31.
81. Galimi F, Verma IM. Opportunities for the use of lentiviral vectors in human gene therapy. Curr Top Microbiol Immunol. 2002;261:245-254.
82. Martin KR, Klein RL, Quigley HA. Gene delivery to the eye using adeno-associated viral vectors. Methods. 2002;28(2):267-275.
83. Lien Y-HH, Lai L-W. Gene therapy for renal disorders: what are the benefits for the elderly? Drugs Aging. 2002;19:553-560.
84. Chamberlain JS. Gene therapy of muscular dystrophy. Hum Mol Genet. 2002;11:2355-2362.
85. Wolf JK, Jenkins AD. Gene therapy for ovarian cancer (review). Int J Oncol. 2002;21:461-468.
86. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 2000;60:249-271.
87. Lever AML. Gene therapy in the fight against AIDS. Expert Opinion on Therapeutic Patents. 1996;6:161-167.
88. Zhao W, Kobayashi M, Hosokawa M, Seth P. Adenoviral vectors for cancer gene therapy. Curr Genomics. 2002;3:163-180.
89. Hale SJ, Green NK. Viral approaches to cancer gene therapy. Expert Opinion on Therapeutic Patents. 2002;12:369-378.
90. Garton KJ, Ferri N, Raines EW. Efficient expression of exogenous genes in primary vascular cells using IRES-based retroviral vectors. Biotechniques. 2002;32(4):830,832,834,836,838,840,842-843.
91. Heider H, Verca SB, Rusconi S, Asmis R. Comparison of lipid-mediated and adenoviral gene transfer in human monocyte-derived macrophages and COS-7 cells. Biotechniques. 2000;28(2):260-265, 268-270.
92. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7:33-40.
93. Favre D, Provost N, Blouin V, et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther. 2001;4:559-566.
94. Timme TL, Hall SJ, Barrios R, Woo SLC, Aguilar-Cordova E, Thompson TC. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Ther. 1998;5:74-82.
95. Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther. 2001;4:586-592.
96. Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther. 2003;3:545-565.
97. Flotte TR, Laube BL. Gene therapy in cystic fibrosis. Chest. 2001;120(suppl 3):124S-131S.
98. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1-2):148-158.
99. Owens RA. Second generation adeno-associated virus type 2-based gene therapy systems with the potential for preferential integration into AAVS1. Curr Gene Ther. 2002;2:145-159.
100. Nyberg-Hoffman C, Aguilar-Cordova E. Instability of adenoviral vectors during transport and its implication for clinical studies. Nat Med. 1999;5:955-957.
101. Cao B, Mytinger JR, Huard J. Adenovirus mediated gene transfer to skeletal muscle. Microsc Res Tech. 2002;58:45-51.
102. Bachrach E, Pelegrin M, Piechaczyk M, Pedersen FS, Duch M. Efficient Gene Transfer into Spleen Cells of Newborn Mice by a Replication-Competent Retroviral Vector. Virology. 2002;293:328-334.
103. Fattal E, Delattre J, Dubernet C, Couvreur P. Liposomes for the delivery of nucleotides and oligonucleotides. S.T.P. Pharma Sciences. 1999;9:383-390.
104. Fattal E, Dubernet C, Couvreur P. Liposome-based formulations for the delivery of oligonucleotides. S.T.P. Pharma Sciences. 2001;11:31-44.
105. Pedroso de Lima MC, Simoes S, Pires P, Faneca H, Duzgunes N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Deliv Rev. 2001;47(2-3):277-294.
106. Hwang SJ, Davis ME. Cationic polymers for gene delivery: designs for overcoming barriers to systemic administration. Curr Opin Mol Ther. 2001;3:183-191.
107. Lemkine GF, Demeneix BA. Polyethylenimines for in vivo gene delivery. Curr Opin Mol Ther. 2001;3:178-182.
108. Lollo CP, Banaszczyk MG, Mullen PM, et al. Poly-L-lysine-based gene delivery systems: synthesis, purification, and application. Methods Mol Med. 2002;69:1-13.
109. Borchard G, Chitosans for gene delivery. Adv Drug Deliv Rev. 2001;52:145-150.
110. LeHoux JG, Grondin F. Some effects of chitosan on liver function in the rat. Endocrinology. 1993;132:1078-1084.
111. Florea BI, Meaney C, Junginger HE, Borchard G. Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures. AAPS PharmSci. 2002;4(3):E12.
112. Koping-Hoggard M, Tubulekas I, Guan H, et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther. 2001;8:1108-1121.
113. Godbey WT, Mikos AG. Recent progress in gene delivery using non-viral transfer complexes. J Control Release. 2001;72(1-3):115-125.
114. Petersen H, Fechner PM, Fischer D, Kissel T. Synthesis, characterization, and biocompatibility of polyethylenimine-graft-poly(ethylene glycol) block copolymer. Macromolecules. 2002;35:6867-6874.
115. Leclercq F, Dubertret C, Pitard B. Scherman D, Herscovici J. Synthesis of glycosylated polyethylenimine with reduced toxicity and high transfecting efficiency. Bioorg Med Chem Lett. 2000;10:1233-1235.
116. Akinc A, Langer R. Measuring the pH environment of DNA delivered using nonviral vectors: implications for lysosomal trafficking. Biotechnol Bioeng. 2002;78:503-508.
117. Mumper RJ, Klakamp SL. Polymeric gene delivery systems for in vivo gene therapy. Drug Targeting and Delivery. 1999;10(Advanced Gene Delivery):143-173.
118. Ward CM, Pechar M, Oupicky D, Ulbrich K, Seymour LW. Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo. J Gene Med. 2002;4:536-547.
119. Jeong JH, Park TG. Poly(l-lysine)-g-poly(d,l-lactic-co-glycolic acid) micelles for low cytotoxic biodegradable gene delivery carriers. J Control Release. 2002;82:159-166.
120. Wolfert MA, Seymour LW. Chloroquine and amphipathic peptide helixes show synergistic transfection in vitro. Gene Ther. 1998;5:409-414.
121. Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects-an update. J Pharm Pharmacol. 2001;53:1047-1067.
122. Kawamata Y, Nagayama Y, Nakao K, et al. Receptor-independent augmentation of adenovirus-mediated gene transfer with chitosan in vitro. Biomaterials. 2002;23:4573-4579.
123. Cui Z, Mumper RJ. Chitosan-based nanoparticles for topical genetic immunization. J Control Release. 2001;75:409-419.
124. Roy K, Mao H-Q. Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunological protection in a murine model of peanut allergy. Nat Med. 1999;5:387-391.
125. Gitsov I, Lambrych KR. Dendrimers: synthesis and applications. Microspheres, Microcapsules & Liposomes. 2002; 5(Dendrimers, Assemblies, Nanocomposites):31-68.
126. Eichman JD, Bielinska AU, Kukowska-Latallo JF, Baker JR, Jr. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharm Sci Technol.Today. 2000;3:232-245.
127. Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm Res. 2002;19:960-967.
128. Yoo H, Juliano RL. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res. 2000;28:4225-4231.
129. Tejada-Berges T, Granai CO, Gordinier M, Gajewski W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther. 2002;2:143-150.
130. Marshall J, Yew NS, Eastman SJ, Jiang C, Scheule RK, Cheng SH. Cationic lipid-mediated gene delivery to the airways. In: Wagner E, ed. Nonviral Vectors for Gene Therapy. San Diego, CA: Academic Press; 1999:39-68.
131. Felgner JH, Kumar R, Sridhar CN, et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem. 1994;269:2550-2561.
132. Hofland HEJ, Shephard L, Sullivan SM. Formation of stable cationic lipid/DNA complexes for gene transfer. Proc Natl Acad Sci U S A. 1996;93:7305-7309.
133. Kang S-H, Zirbes EL, Kole R. Delivery of antisense oligonucleotides and plasmid DNA with various carrier agents. Antisense Nucleic Acid Drug Dev. 1999;9:497-505.
134. Lappalainen K, Jaaskelainen I, Syrjanen K, Urtti A, Syrjanen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res. 1994;11:1127-1131.
135. Patil SD, Rhodes DG, Burgess DJ. Anionic liposomal delivery system for DNA transfection. The AAPS Journal. 2004;6:E29.
136. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res. 2000;17:521-525.
137. Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta. 1997;1329:345-356.
138. Freimark BD, Blezinger HP, Florack VJ, et al. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid:cationic lipid complexes. J Immunol. 1998;160:4580-4586.
139. Lee H, Williams SKR, Allison SD, Anchordoquy TJ. Analysis of self-assembled cationic lipid-DNA gene carrier complexes using flow field-flow fractionation and light scattering. Anal Chem. 2001;73:837-843.
140. Audouy S, Molema G, De Leij L, Hoekstra D. Serum as a modulator of lipoplex-mediated gene transfection: dependence of amphiphile, cell type and complex stability. J Gene Med. 2000;2:465-476.
141. Liu F, Qi H, Huang L, Liu D. Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ther. 1997;4:517-523.
142. Wheeler CJ, Felgner PL, Tsai YJ, et al. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci U S A. 1996;93:11454-11459.
143. Fillion P, Desjardins A, Sayasith K, Lagace J. Encapsulation of DNA in negatively charged liposomes and inhibition of bacterial gene expression with fluid liposome-encapsulated antisense oligonucleotides. Biochim Biophys Acta. 2001;1515:44-54.
144. Lakkaraju A, Dubinsky JM, Low WC, Rahman Y-E. Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes. J Biol Chem. 2001;276:32000-32007.
145. Patil SD, Rhodes DG. Conformation of oligodeoxynucleotides associated with anionic liposomes. Nucleic Acids Res. 2000;28:4125-4129.
146. Patil SD, Rhodes DG, Burgess DJ. Biophysical characterization of anionic lipoplexes. Biochim Biophys Acta.-Biomembranes. 2005; In Press.
147. Lee RJ, Huang L. Lipidic vector systems for gene transfer. Crit Rev Ther Drug Carrier Syst. 1997;14:173-206.
148. Guo W, Gosselin MA, Lee RJ. Characterization of a novel diolein-based LPDII vector for gene delivery. J Control Release. 2002;83:121-132.
149. Perrie Y, Gregoriadis G. Liposome-entrapped plasmid DNA: characterization studies. Biochim Biophys Acta. 2000;1475:125-132.
150. Venugopalan P, Jain S, Sankar S, Singh P, Rawat A, Vyas SP. pH-Sensitive liposomes: mechanism of triggered release to drug and gene delivery prospects. Pharmazie. 2002;57:659-671.
151. Maclean AL, Symonds G, Ward R. Immunoliposomes as targeted delivery vehicles for cancer therapeutics (Review). Int J Oncol. 1997;11:325-332.
152. Legendre JY, Szoka FC Jr. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. Pharm Res. 1992;9:1235-1242.
153. Reddy JA, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J Control Release. 2000;64(1-3):27-37.
154. Sviridov YV, Zhdanov RI, Podobed OV, Tsvetkova TA, Konstantinov I, Bogdanenko EV. The LacZ gene transfer into L929 cells and [14C]-DNA tissue distribution following intraperitoneal administration of new pH-sensitive lipoplexes in mice. Cytobios. 2001;106:(suppl 1),7-14.
155. Xu L, Huang C-C, Huang W, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002;1:337-346.
156. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after IV administration. Proc Natl Acad Sci U S A. 2001;98:12754-12759.
157. Khaw BA, da Silva J, Vural I, Narula J, Torchilin VP. Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. J Control Release. 2001:75(1-2):199-210.
158. Krauss WC, Park JW, Kirpotin DB, Hong Y, Benz CC. Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. Breast Disease. 2000;11:113-124.
159. Mannisto M, Vanderkerken S, Toncheva V, et al. Structure-activity relationships of poly(l-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. J Control Release. 2002;83:169-182.